Allterum’s Antibody

Allterum is developing 4A10, a monoclonal antibody targeted against IL-7Rα. IL-7Rα is part of a receptor complex located on T-cell and B-cell leukemia cells. Especially in the context of T-cell leukemia cells, IL-7Rα plays a critical role in driving cancer growth. IL-7Rα is frequently expressed at a higher level, or is more active, in T-cell leukemia cells, and has been posited as playing a key role in ALL oncogenesis and chemotherapy-resistance. Allterum’s 4A10 antibody is the first immunotherapy approach to target IL-7Rα in leukemia. 4A10 uses the patient’s own immune system to target leukemia cells for destruction. 4A10 is currently in development for the treatment of relapsed pediatric leukemia.

4A10 and IL-7Rα in Scientific Literature

IL-7R is highlighted for its potential oncogenic effects in T-cell ALL

IL-7R signaling can drive leukemia development, acceleration, and resistance to chemotherapy

Targeting IL-7R with an antibody-drug conjugate is efficacious in models of T-cell ALL

IL-7R may play a key role in driving Ph-like and Ph+ B-cell acute lymphoblastic leukemia

IL-7Rα is a promising target for the treatment of pediatric acute lymphoblastic leukemia


Advancing an innovative solution for a critical and unmet medical need